

The 23rd AHWP Annual Meeting

Chinese Taipei Regulatory Update

..... Cheng-Ning Wu

Division of Medical Devices and Cosmetics, TFDA

October 25, 2018
Kuala Lumpur, Malaysia




衛生福利部
食品藥物管理署
Food and Drug Administration

<http://www.fda.gov.tw/>

General Overview


Medical Device Regulatory Framework




- Beginning of registration: 1973
- GMP* implementation: 1999
- Reclassification: 2000
- No. of registered MD licenses: 44,694 (as of July 2018) (76% Imported; 24% Domestic)
- No. of registered MD manufacturers: 1,516 (as of 2017)

*Adoption of ISO 13485

Medical Device Life Cycle Management




Basis of Medical Device Regulation




Premarket Regulation

Risk Based Regulation



*QSD: Quality System Documentation

Premarket Registration



Medical Device License Database



西藥、醫療器材、含藥化粧品許可證查詢

許可證字號	<input type="text"/> 字第 <input type="text"/> 號		
許可證種類	<input type="text"/>	註銷狀態	<input type="text"/>
中文品名	<input type="text"/>	英文品名	<input type="text"/>
醫療器材主分類	<input type="text"/>		
醫療器材次分類	<input type="text"/>		
限制項目	<input type="text"/>		
劑型(粗)	<input type="text"/>	劑型(細)	<input type="text"/>
申請商名稱	<input type="text"/>	適應症(藥品)	<input type="text"/>
製造廠名稱	<input type="text"/>	效能(醫療器材)	<input type="text"/>
國別	<input type="text"/>	用途(化粧品)	<input type="text"/>
藥品類別	<input type="text"/>	單/複方別	<input type="text"/>
藥理治療分類(ATC碼)	<input type="text"/>	藥理治療分類(AHFS/DI碼)	<input type="text"/>
成分	<input type="text"/>	成分	<input type="text"/>
成分	<input type="text"/>		
排序方式	許可證字號 <input type="text"/>	驗證碼	<input type="text"/>
		<input type="button" value="重新產生"/>	

<http://www.fda.gov.tw/MLMS/H0001.aspx>

Postmarket Regulation

Postmarket Surveillance

Manufacturer

- Adverse event / product defect
- Clinical trial adverse event
- Periodic Safety Update Report (PSUR)
- Voluntary recall notification

Asian Harmonization Working Party (AHWP)
Safety Alert Dissemination System (SADS)

Local Health Authority

- Investigation, seizure, and sampling of non-compliant product




Active surveillance of
international post-market
safety information

Consumer & Medical Personnel

- Adverse device reaction (ADR)
- Product defect

TFDA




**National ADR
Reporting Center**

Medical Device
Recall




Medical Devices Act (draft)

Reasons for Promoting Medical Devices Act (MDA)



Regulatory Framework for Total Product Life Cycle in MDA



Main Points for Establishing MDA(1)

To advance industrial technology development and product innovation



- ✓ Incorporate manufacturers that engage in design and marketing of medical devices under their name
- ✓ Encourage industry development & product innovation, and in order to benefit patients, incorporate mechanisms of marketing acceleration and support for newly innovative medical devices

To enhance regulation of diversified technology industry of medical devices



- ✓ Incorporate regulation of business undertakings that perform maintenance and/or repair of medical devices
- ✓ Require technicians having professional background & experience with educational training to be employed according to different medical device categories in order to enhance professional management
- ✓ Further regulate the types of sale and supply for specific medical devices

Main Points for Establishing MDA (2)

To strengthen management of product flow and distribution quality



- ✓ Assign responsibility to medical device firms and medical institutions for establishing and maintaining data on direct supply sources and flow of products
- ✓ Promote quality management of medical device distribution to ensure that product quality would not be impaired during distribution process

To fulfill regulation of medical devices by risk classification



- ✓ Registration system for a portion of the low risk medical devices would be changed to online listing and the validity of registration would be extended by filing annual report

Main Points for Establishing MDA (3)



To set up framework for regulating clinical trials

- ✓ Incorporate relevant practices of clinical trial
- ✓ Stipulate that medical device clinical trials which are conducted and have been announced as having no significant risks may be exempt from applying for competent authority's approval



To reinforce regulation of medical device postmarket safety surveillance

- ✓ Certain specific high risk medical devices must conduct postmarket surveillance and medical institutions should cooperate accordingly
- ✓ Firms would be tasked with conducting voluntary surveillance of marketed products' risk management and necessary corrective and preventive measures

Recent Achievements

Important Achievements in 2017 & 2018

I. Develop globally harmonized medical device regulations

1. Publicly announce guidances for emerging medical devices

- Announced “Guidance for the Management of Additive Manufactured (3D Printing) Medical Devices”
- Announced “Guidance for the Validation of Medical Device Software”
- Announced technical guidances for dengue virus serological reagents, RNA preanalytical systems, influenza virus nucleic acid detection assays, and quality control materials for in vitro diagnostics

- Initiated the draft of regulatory guidance for Molecular Testing, Industrial Laboratory Testing, and Service Management of Precision Medicine (LDTs)
- Initiated the draft of medical device cybersecurity guidance
- Announced the list of recognized standards for 2018 and the list of withdrawn or revised standards that were previously recognized

Proactively^{2.}
address key
regulatory issues

Important Achievements in 2017 & 2018 (2)

II. Accelerate time to market for medical devices

3. Enhance review efficiency and quality

- Announced the pilot of “Priority Review Program for Medical Devices” to accelerate time to market for emerging medical devices:
5 cases were received and out of which 3 obtained marketing approval


III. Establish a high quality environment for industry development

- Completed the recruit of 3 seeded hospitals for medical device clinical trials (Cathay General Hospital, Chung Shan Medical University Hospital, Tri-Service General Hospital) and conducted programs that improved clinical trial quality
- Elaborately designed basic and advanced medical device clinical trial courses for Taiwan, and produced a series of 36-hour digital high-quality learning materials on medical device clinical trials

4. Optimize clinical trial environment

Future Priorities

Key Points of Policy Administration



Thank you for your attention!

.....



衛生福利部
食品藥物管理署
Food and Drug Administration

<http://www.fda.gov.tw/>